High-Content Biology Platform

Robin Ketteler (UCL MRC Laboratory for Molecular Biology)

We employ high-throughput screening technologies as a means to identify novel components that modify cellular signal transduction pathways and autophagy. To this end, we are developing novel screening technologies based on arrayed CRISPR libraries and using knockout cell panels. Our studies will generate strategies for the identification of potential therapeutic targets in diseases such as cancer and neuro-degeneration. Further, we have the resources and expertise to translate these basic research findings into a drug discovery program to identify potential therapeutic lead compounds.